MHRA publishes updates to prescribing information for CAPs in the event of a no-deal Brexit.

Update: In March 2019, we posted on the “MHRA’s extensive no-deal guidance updates for pharma and medtech“. Following on from the MHRA’s published guidance on ‘grandfathering’ and managing the lifecycle changes of medicinal products (see here), the MHRA has released an update in regards to the time period companies must submit the relevant information. The […]